U.S. markets closed

The Zacks Analyst Blog Highlights: Intel, Novartis, Toyota Motor, Union Pacific and Biogen

Zacks Equity Research

For Immediate Release

Chicago, IL – April 28, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Intel INTC, Novartis NVS, Toyota Motor TM, Union Pacific UNP and Biogen BIIB.

Here are highlights from Monday’s Analyst Blog:

Top Research Reports for Intel, Novartis and Toyota

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Intel, Novartis and Toyota Motor. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Intel’s shares have underperformed the Zacks General Semiconductor industry over the past six months (+3.7% vs. +11.5%). The Zacks analyst believes that robust mix of high-performance second-generation Xeon Scalable processors and solid demand from Cloud service providers is expected to drive near-term growth.

The company is also making advancements in the IoT space, courtesy of product introductions and tie ups. Moreover, Intel is witnessing strong momentum for its first 10-nanometer (nm) mobile CPU.

Notably, the company has not provided 2020 guidance citing coronavirus crisis-induced business uncertainty. Further, declining PC total addressable market, higher expenses pertaining to 10-nm ramp up and constrained supply amid coronavirus outbreak in China remain concerns.

Shares of Novartis have gained +11% over the past year against the Zacks Large Cap Pharmaceuticals industry’s rise of +12.4%. The Zacks analyst believes that pipeline setbacks and generic competition for additional drugs are concerning.

Novartis has a strong oncology portfolio and a formidable generics business. The solid performance of key drugs like Cosentyx and Entresto, and contribution from gene therapy, Zolgensma, have boosted the performance in recent times and offset the impact of generic competition for legacy drugs. New launches like Piqray, Mayzent and Beovu should further boost sales.

The biosimilar portfolio also gains traction with new key approvals. The deep pipeline is encouraging as well. Novartis is also focusing on developing treatments for coronavirus and a positive outcome will boost the stock significantly. However, price erosion in the United States has adversely impacted the generics business.

Toyota’s shares have lost -13.3% over the past three months against the Zacks Foreign Automotive industry’s fall of -18.4%. The Zacks analyst believes that expanding portfolio of product lines is driving Toyota’s prospects.

In order to capitalize on the accelerated global shift to electric cars, the auto giant of Japan is focusing on developing electric and autonomous vehicles. Toyota is working on hydrogen fuel stations in collaboration with various partners. The company aims to achieve half its global sales from electric vehicles by 2025. However, anticipating a slowdown in India, China, Indonesia and Thailand, the company narrowed its annual vehicle sales target for fiscal 2020.

Moreover, coronavirus woes and high research and development expenses on advanced technologies for the development of EVs and driverless cars are also likely to dent near-term margins. Its high debt levels also remain a concern. As such, investors are recommended to wait for a better entry point.

Other noteworthy reports we are featuring today include Union Pacific and Biogen.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339



Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Biogen Inc. (BIIB) : Free Stock Analysis Report
Union Pacific Corporation (UNP) : Free Stock Analysis Report
Intel Corporation (INTC) : Free Stock Analysis Report
Toyota Motor Corporation (TM) : Free Stock Analysis Report
Novartis AG (NVS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research